Breaking News Instant updates and real-time market news.

ORTX

Orchard Therapeutics

$13.99

1.14 (8.87%)

, SLDB

Solid Biosciences

$7.17

0.02 (0.28%)

11:53
02/08/19
02/08
11:53
02/08/19
11:53

Goldman says Orchard track record stands out amid disappointments in gene space

Goldman Sachs analyst Graig Suvannavejh noted that February 7 was "a day of disappointment" in the gene therapy and gene editing space, as Solid Biosciences (SLDB) and Sangamo (SGMO) both reported clinical efficacy data that missed investor expectations and "perhaps also raised concerns about the long-term promise of gene-based approaches." Within this context, he pointed out that he believes Orchard Therapeutics (ORTX) has "the most robust clinical experience in gene therapy, with over 150 patients treated across multiple product candidates and indications." The analyst, who expects new clinical data for Orchard candidates OTL-101 and OTL-102 to be presented later this month to re-affirm his confidence, reiterated his Buy rating and $21 price target on Orchard shares.

ORTX

Orchard Therapeutics

$13.99

1.14 (8.87%)

SLDB

Solid Biosciences

$7.17

0.02 (0.28%)

SGMO

Sangamo

$7.89

-0.455 (-5.46%)

ORTX Orchard Therapeutics
$13.99

1.14 (8.87%)

12/17/18
GSCO
12/17/18
NO CHANGE
GSCO
Goldman starts Argenx at Conviction Buy, upgrades Orchard to Buy
Goldman Sachs analyst Graig Suvannavejh initiated coverage of Argenx (ARGX) with a Buy rating and $154 price target while adding the shares to his firm's Pan-Europe Conviction List. The company has "unique" antibody technology and a "promising" Phase 3 asset in efgartigimod for the treatment of severe autoimmune disorders, Suvannavejh tells investors in a research note. He believes efgartigimod has a "best-in-class profile" and could reach peak global risk-adjusted sales of EUR 1.6B. Further, Argenx has been advancing cusatuzumab, a novel anti-CD70 antibody for potential use in blood cancers, says the analyst. Suvannavejh also upgraded Orchard Therapeutics (ORTX) to Buy from Neutral and raised his price target for the shares to $21 from $18. The analyst projects $1.2B in peak global sales or Orchard's leading programs and sees "limited" clinical risk. With multiple sets of clinical data expected throughout 2019 on three late-stage candidates currently in registrational trials, anticipated news flow in 2019 could position shares of Orchard well for potential appreciation, Suvannavejh writes.
12/17/18
GSCO
12/17/18
UPGRADE
Target $21
GSCO
Buy
Orchard Therapeutics upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Graig Suvannavejh upgraded Orchard Therapeutics to Buy citing increased confidence in the company's pipeline. The analyst raised his price target for the shares to $21 from $18.
11/26/18
11/26/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Nvidia (NVDA) initiated with an Outperform at Credit Suisse. 2. Orchard Therapeutics (ORTX) initiated with an Outperform at Wedbush and Cowen, an Overweight at JPMorgan, and a Neutral at Goldman Sachs. 3. Twist Bioscience (TWST) initiated with an Outperform at Cowen and Baird as well as a Neutral at JPMorgan. 4. Axonics (AXNX) initiated with a Buy at BofA/Merrill and SunTrust, an Outperform at Wells Fargo, and an Overweight at Morgan Stanley. 5. Gamida Cell (GMDA) initiated with a Buy at Needham. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/26/18
COWN
11/26/18
INITIATION
Target $27
COWN
Outperform
Orchard Therapeutics initiated with an Outperform at Cowen
Cowen analyst Ritu Baral initiated Orchid Therapeutics with an Outperform rating as she believes their ex vivo GT pipeline is the richest today in terms of both the number of programs and patient experience. Baral has a $27 price target on Orchard Therapeutics shares.
SLDB Solid Biosciences
$7.17

0.02 (0.28%)

02/07/19
LEER
02/07/19
DOWNGRADE
Target $8
LEER
Market Perform
Solid Biosciences downgraded to Market Perform from Outperform at SVB Leerink
SVB Leerink analyst Joseph Schwartz downgraded Solid Biosciences to Market Perform and cut his price target for the shares to $8 from $50.
02/07/19
PIPR
02/07/19
NO CHANGE
Target $200
PIPR
Overweight
Piper says Sarepta position strengthened by Solid's 'dismal expression' data
After Solid Biosciences (SLDB) reported preliminary patient biopsy data with SGT-001, the company's AAV9 microdystrophin gene therapy, Piper Jaffray analyst Danielle Brill said she expected significantly lower expression levels than Sarepta (SRPT) generated, but the "dismal expression" reported is particularly concerning as it suggests lack of efficacy may be driven by something other than a sub-therapeutic dose. She also believes pushing the dose high enough to compete on efficacy could be a challenge given the safety profile of SGT-001. She views today's news as a "considerable setback" for Solid and believes it strengthens Sarepta's "front-runner position," Brill tells investors. She maintains an Overweight rating and $200 price target on Sarepta shares.
02/08/19
SBSH
02/08/19
UPGRADE
Target $8
SBSH
Neutral
Solid Biosciences upgraded to Neutral from Sell at Citi
Citi analyst Joel Beatty upgraded Solid Biosciences to Neutral with an $8 price target following yesterday's selloff.
02/08/19
SBSH
02/08/19
UPGRADE
Target $8
SBSH
Neutral
Citi upgrades Solid Biosciences to Neutral after Sell thesis played out
Citi analyst Joel Beatty upgraded Solid Biosciences to Neutral from Sell while lowering his price target for the shares to $8 from $31. The analyst says that with the initial clinical data for SGT-001 announced yesterday, his Sell thesis has played out. He moves to a Neutral rating because he believes that the next dosing cohort is "unlikely to generate strong enough data to support a commercially competitive profile."
SGMO Sangamo
$7.89

-0.455 (-5.46%)

02/08/19
JEFF
02/08/19
NO CHANGE
Target $23
JEFF
Buy
Jefferies sees opportunity in Sangamo after selloff, drops target to $23
Jefferies analyst Maury Raycroft says his Buy thesis on Sangamo Therapeutics is unchanged following yesterday's update. The analyst lowered his price target for the shares to $23 from $26 and maintains a Buy rating. Sangamo demonstrated successful in vivo editing, Raycroft tells investors in a research note. The analyst has confidence in the company's update, noting Sangamo was able to detect an albumin-IDS mRNA transcript in a liver biopsy aspirate that extracted around 100,000-300,000 cells for analysis. Further, concern about patient six and the transaminitis is likely an overreaction as liver enzyme elevation is consistent across gene therapy programs, adds the analyst. Raycroft sees opportunity in Sangamo shares following yesterday's selloff.
11/14/18
JPMS
11/14/18
DOWNGRADE
Target $11
JPMS
Neutral
JPMorgan downgrades Sangamo to Neutral on 'growing skepticism'
JPMorgan analyst Eric Joseph downgraded Sangamo Therapeutics (SGMO) to Neutral from Overweight and lowered his price target for the shares to $11 from $35. Following the company's Q3 results, the analyst has "growing skepticism" about its lead development programs and "their potential for value creation over the foreseeable future." Visibility into the initial efficacy of the SB-525 / Hemophilia A program "continues to elude, now with indefinite timelines," Joseph tells investors in a research note. With relatively slower recruitment to date, the analyst struggles to see how SB-525 closes ground with the two later-stage competitor FVIII gene therapy programs from BioMarin (BMRN) and Spark Therapeutics (ONCE).
02/07/19
PIPR
02/07/19
NO CHANGE
Target $75
PIPR
Overweight
Crispr Therapeutics sell-off 'unfounded,' Overweight reiterated at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $75 price target on Crispr Therapeutics (CRSP). In a research note to investors, Tenhoff noted that Crispr and the broader gene editing space are selling off in reaction to Sangamo's (SGMO) presentation of interim data from the first in vivo gene editing study at WORLD Symposium 2019, which showed no meaningful changes in IDS or GAG levels in six patients after 23 weeks. Tenthoff says he does not see read-through to Crispr and that he believes CTX001 ex vivo approach and biological rational of targeting fetal hemoglobin de-risk and differentiate Crispr and that he is a buyer on "unfounded" sell-off in shares.
02/07/19
WELS
02/07/19
NO CHANGE
Target $24
WELS
Outperform
Wells Fargo says buy Sangamo on today's 'overdone' selloff
Wells Fargo analyst Jim Birchenough lowered his price target for Sangamo Therapeutics to $24 from $39 following today's update for in-vivo gene editing in mucopolysaccharidosis type I and II. While overall results are disappointing in terms of markers of sustainable efficacy and suggest further optimization required of gene editing efficiency and delivery, individual patient validation with significant iduronate-2-sulfatase enzyme production in one of two high dose MPSII patients and evidence of enzyme production in MPSI is encouraging, Birchenough tells investors in an intraday research note titled "Over Reaction To In-Vivo Gene Editing Update." The analyst believes Sangamo shares are "oversold" on today's news and recommends buying on the weakness. He maintains an Outperform rating on the name. Sangamo shares in in afternoon trading are down 36%, or $4.28, to $7.74.

TODAY'S FREE FLY STORIES

NOVA

Sunnova Energy

$11.13

0.089 (0.81%)

21:22
08/19/19
08/19
21:22
08/19/19
21:22
Initiation
Sunnova Energy initiated at KeyBanc »

Sunnova Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

SPY

SPDR S&P 500 ETF Trust

$292.31

3.52 (1.22%)

, SPX

S&P 500

$0.00

(0.00%)

20:54
08/19/19
08/19
20:54
08/19/19
20:54
Periodicals
Trump administration considering steps on economy if conditions worsen, NYT says »

White House officials…

SPY

SPDR S&P 500 ETF Trust

$292.31

3.52 (1.22%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSS

Kohl's

$48.20

2.69 (5.91%)

, TJX

TJX

$51.55

0.13 (0.25%)

20:25
08/19/19
08/19
20:25
08/19/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KSS

Kohl's

$48.20

2.69 (5.91%)

TJX

TJX

$51.55

0.13 (0.25%)

MDT

Medtronic

$104.15

1.42 (1.38%)

HD

Home Depot

$207.98

4.335 (2.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 20

    Aug

  • 20

    Aug

  • 20

    Aug

  • 04

    Sep

  • 09

    Sep

BHP

BHP Group

$49.12

0.31 (0.64%)

19:32
08/19/19
08/19
19:32
08/19/19
19:32
Hot Stocks
BHP Group sees China and global economic growth slowing »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

BHP

BHP Group

$49.12

0.31 (0.64%)

19:25
08/19/19
08/19
19:25
08/19/19
19:25
Earnings
BHP Group reports FY19 Net profit up 124% at $8.31B »

Reports FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

AAPL

Apple

$210.32

3.88 (1.88%)

19:09
08/19/19
08/19
19:09
08/19/19
19:09
Periodicals
Apple aims for November launch of Apple+, Bloomberg reports »

Apple is targeting a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACN

Accenture

$195.19

2.005 (1.04%)

19:04
08/19/19
08/19
19:04
08/19/19
19:04
Hot Stocks
Accenture acquires Parker Fitzgerald, terms not disclosed »

Accenture has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Oct

BIDU

Baidu

$104.28

7.63 (7.89%)

, NBRV

Nabriva Therapeutics

$2.21

-0.06 (-2.64%)

18:47
08/19/19
08/19
18:47
08/19/19
18:47
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Baidu…

BIDU

Baidu

$104.28

7.63 (7.89%)

NBRV

Nabriva Therapeutics

$2.21

-0.06 (-2.64%)

MRNA

Moderna

$13.41

0.235 (1.78%)

VSLR

Vivint Solar

$8.30

0.3 (3.75%)

FN

Fabrinet

$56.40

0.77 (1.38%)

IQ

iQIYI

$18.10

1.02 (5.97%)

MRUS

Merus

$18.46

1.75 (10.47%)

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 19

    Aug

  • 19

    Aug

  • 19

    Aug

  • 19

    Aug

  • 20

    Aug

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 04

    Sep

  • 09

    Sep

  • 12

    Sep

ET

Energy Transfer LP

$13.77

0.3 (2.23%)

18:40
08/19/19
08/19
18:40
08/19/19
18:40
Periodicals
Energy Transfer LP performing maintenance on WTG pipeline, Reuters says »

A spokeswoman for Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$210.32

3.88 (1.88%)

, SNE

Sony

$55.71

-0.01 (-0.02%)

18:20
08/19/19
08/19
18:20
08/19/19
18:20
Periodicals
Apple allocates over $6B for original TV shows and movies, FT says »

Apple (AAPL) has budgeted…

AAPL

Apple

$210.32

3.88 (1.88%)

SNE

Sony

$55.71

-0.01 (-0.02%)

NFLX

Netflix

$309.40

6.66 (2.20%)

DIS

Disney

$135.33

0.14 (0.10%)

T

AT&T

$35.40

0.42 (1.20%)

CBS

CBS

$44.21

0.38 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 05

    Sep

  • 23

    Sep

  • 23

    Oct

LGIH

LGI Homes

$78.56

3.36 (4.47%)

18:01
08/19/19
08/19
18:01
08/19/19
18:01
Hot Stocks
LGI Homes opens two new communities in greater Seattle market »

LGI Homes announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,816.29

24.47 (1.37%)

18:01
08/19/19
08/19
18:01
08/19/19
18:01
Hot Stocks
Amazon.com to expand in Utah with new new fulfillment center »

Amazon.com announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

WMT

Walmart

$113.76

0.77 (0.68%)

18:00
08/19/19
08/19
18:00
08/19/19
18:00
Hot Stocks
Walmart to pay $100,000 to settle EEOC disability discrimination suit »

Wal-Mart Stores East, LP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

X

U.S. Steel

$12.42

1.13 (10.01%)

17:58
08/19/19
08/19
17:58
08/19/19
17:58
Periodicals
U.S. Steel to lay off hundreds of workers at Great Lakes plant, Reuters says »

U.S. Steel plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

17:53
08/19/19
08/19
17:53
08/19/19
17:53
Hot Stocks
Breaking Hot Stocks news story on Sarepta »

Sarepta falls over 4% or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

17:52
08/19/19
08/19
17:52
08/19/19
17:52
Hot Stocks
FDA's CRL to Sarepta's golodirsen citing risk of infection, renal toxicity »

Sarepta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

BSX

Boston Scientific

$42.74

0.59 (1.40%)

17:41
08/19/19
08/19
17:41
08/19/19
17:41
Hot Stocks
Boston Scientific's ImageReady MRI labeling receives FDA approval »

Boston Scientific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 09

    Sep

  • 13

    Nov

AMZN

Amazon.com

$1,816.29

24.47 (1.37%)

, GOOG

Alphabet

$1,198.01

21.07 (1.79%)

17:35
08/19/19
08/19
17:35
08/19/19
17:35
Periodicals
State AGs to proceed with antitrust investigation of big tech, WSJ reports »

A group of state…

AMZN

Amazon.com

$1,816.29

24.47 (1.37%)

GOOG

Alphabet

$1,198.01

21.07 (1.79%)

GOOGL

Alphabet Class A

$1,199.94

21.25 (1.80%)

FB

Facebook

$186.22

2.8 (1.53%)

MSFT

Microsoft

$138.43

2.3 (1.69%)

AAPL

Apple

$210.32

3.88 (1.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 10

    Sep

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

FB

Facebook

$186.22

2.8 (1.53%)

17:31
08/19/19
08/19
17:31
08/19/19
17:31
Periodicals
FTC head says breaking up Facebook could be complicated, FT reports »

Federal Trade Commission…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

MPW

Medical Properties Trust

$18.28

0.13 (0.72%)

17:28
08/19/19
08/19
17:28
08/19/19
17:28
Hot Stocks
Medical Properties Trust COO sells 100K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

WMT

Walmart

$113.76

0.77 (0.68%)

17:17
08/19/19
08/19
17:17
08/19/19
17:17
Periodicals
Walmart's U.S. Chief Marketing Officer Barbara Messing is leaving, AdAge says »

Walmart U.S. Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

MAXR

Maxar Technologies

$6.49

0.185 (2.93%)

17:12
08/19/19
08/19
17:12
08/19/19
17:12
Hot Stocks
Maxar Technologies' MDA awarded Canadian Space Agency contract »

MDA, a Maxar company, has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCI

Rogers Communications

$51.30

0.21 (0.41%)

17:06
08/19/19
08/19
17:06
08/19/19
17:06
Hot Stocks
Rogers 'disappointed' by CRTC decision on broadband wholesale rates »

Rogers Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IQ

iQIYI

$18.10

1.02 (5.97%)

17:05
08/19/19
08/19
17:05
08/19/19
17:05
Hot Stocks
Breaking Hot Stocks news story on iQIYI »

iQIYI down over 6% or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

IQ

iQIYI

$18.10

1.02 (5.97%)

17:03
08/19/19
08/19
17:03
08/19/19
17:03
Hot Stocks
iQIYI reports Q2 total subscribing members 100.5M, up 50% from last year »

iQIYI's number of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.